AR013021A1 - Anticuerpo monoclonal que reconoce el oligosacárido ácido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composiciones farmacéuticas que lo contienen. - Google Patents

Anticuerpo monoclonal que reconoce el oligosacárido ácido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composiciones farmacéuticas que lo contienen.

Info

Publication number
AR013021A1
AR013021A1 ARP990100494A ARP990100494A AR013021A1 AR 013021 A1 AR013021 A1 AR 013021A1 AR P990100494 A ARP990100494 A AR P990100494A AR P990100494 A ARP990100494 A AR P990100494A AR 013021 A1 AR013021 A1 AR 013021A1
Authority
AR
Argentina
Prior art keywords
galactose
glucose
glycolylated
monoclonal antibody
oligosaccharide
Prior art date
Application number
ARP990100494A
Other languages
English (en)
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CU1998022A priority Critical patent/CU22731A1/es
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of AR013021A1 publication Critical patent/AR013021A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

La presente invencion se relaciona con la rama de la inmunología y la medicina humana, en particular con la generacion y seleccion de un anticuerpomonoclonal (AcM) que reconoce el oligosacárido Acido Sialico N-Glicolilado- Galactosa-Glucosa (N-GcNeu- Gal-Glu) presente en tumores malignos. Uno de losobjetos de esta invencion es proporcionar un AcM de tipo IgG1 que poseen la característica de reconocer con alta especificidad la secuencia oligosacáridicaAcido Siálico N-Glicolilado-Galac tosa-Glucosa presente en tejidos malignos de mama así como en melanomas y tumores de hígado, estomago, colon, recto y rinon.También posee la capacidad de provocar citolisis directa en las células tumorales portadoras de esta secuencia oligo sacarídica,de aquí que pueda serusado para el diagnostico y el tratamiento de ciertas enfermedades neoplásicas. Otro objeto de la presente invencion es proporcionar el hibridoma productor deAcM mencionado, así como la composicion farmacéutica que lo contiene,para el tratamiento de enfermedades neoplásicas.
ARP990100494A 1998-02-05 1999-02-05 Anticuerpo monoclonal que reconoce el oligosacárido ácido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composiciones farmacéuticas que lo contienen. AR013021A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU1998022A CU22731A1 (es) 1998-02-05 1998-02-05 Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen

Publications (1)

Publication Number Publication Date
AR013021A1 true AR013021A1 (es) 2000-11-22

Family

ID=5459215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100494A AR013021A1 (es) 1998-02-05 1999-02-05 Anticuerpo monoclonal que reconoce el oligosacárido ácido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composiciones farmacéuticas que lo contienen.

Country Status (17)

Country Link
US (1) US6429295B1 (es)
EP (1) EP0972782B1 (es)
JP (1) JP4125383B2 (es)
CN (1) CN1149224C (es)
AR (1) AR013021A1 (es)
AT (1) AT250085T (es)
AU (1) AU764632B2 (es)
BR (1) BR9904773A (es)
CA (1) CA2286288C (es)
CO (1) CO4810341A1 (es)
CU (1) CU22731A1 (es)
DE (1) DE69911322T2 (es)
DK (1) DK0972782T3 (es)
ES (1) ES2209391T3 (es)
MX (1) MXPA99009082A (es)
PT (1) PT972782E (es)
WO (1) WO1999040119A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156045D0 (en) * 2000-12-08 2003-12-23 Childrens Memorial Hospital Compositions containing gangliosides for use in the treatment of skin disorders
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
CA2510250A1 (en) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CN101835319B (zh) 2009-03-13 2014-05-07 奥斯兰姆有限公司 用于电子镇流器的外壳
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan-Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US9433686B2 (en) 2011-01-31 2016-09-06 The Regents Of The University Of California Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
CU24070B1 (es) 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
CU24120B1 (es) 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
US10722523B2 (en) 2015-03-17 2020-07-28 The Regents Of The University Of California Chemoimmunotherapy for epithelial cancer
EP3271398A1 (en) 2015-03-17 2018-01-24 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
AU8212291A (en) * 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours

Also Published As

Publication number Publication date
CA2286288C (en) 2010-09-28
WO1999040119A9 (es) 2000-07-06
US6429295B1 (en) 2002-08-06
CA2286288A1 (en) 1999-08-12
MXPA99009082A (es) 2002-04-24
AU2407899A (en) 1999-08-23
AU764632B2 (en) 2003-08-28
WO1999040119A1 (es) 1999-08-12
CO4810341A1 (es) 1999-06-30
JP4125383B2 (ja) 2008-07-30
DK0972782T3 (da) 2004-02-02
DE69911322T2 (de) 2004-07-01
DE69911322D1 (de) 2003-10-23
JP2001509684A (ja) 2001-07-24
BR9904773A (pt) 2000-03-21
CN1149224C (zh) 2004-05-12
ES2209391T3 (es) 2004-06-16
CN1256696A (zh) 2000-06-14
PT972782E (pt) 2004-02-27
EP0972782B1 (en) 2003-09-17
CU22731A1 (es) 2002-02-28
AT250085T (de) 2003-10-15
EP0972782A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
AR013021A1 (es) Anticuerpo monoclonal que reconoce el oligosacárido ácido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composiciones farmacéuticas que lo contienen.
Epenetos et al. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours
ES2080717T3 (es) Hibridomas productores de anticuerpos monoclonales para nuevos epitopos de mucina.
CN101679526A (zh) 介导癌细胞细胞毒性的人源化和嵌合抗trop-2抗体
RU2468036C2 (ru) Антитела, модифицирующие раковые заболевания
CN105753988A (zh) 用于治疗癌症的单克隆抗体
CN101743255A (zh) 抗癌细胞毒性单克隆抗体
RU2016124229A (ru) Полипептиды антител и их применения
MX9304501A (es) Quimioterapia para cancer.
CN102008732A (zh) 一种叶酸偶联抗体药物及其制备方法与应用
CN101622341A (zh) 减轻癌性疾病的抗体
Tsunoda et al. Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy
Pearson et al. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice
Gerretsen et al. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F (ab') 2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG
Kameya et al. The sign of Leser-Trélat associated with carcinoma of the stomach.
YU63702A (sh) Novo antitelo sa specifičnošću za rak debelog creva
CN101687931A (zh) 抗癌细胞毒性单克隆抗体
CN101015703B (zh) 一种反义显像剂及其反义寡核苷酸
CN101535471B (zh) 修饰癌症病的抗体180706-02
Carrel et al. Expression of Class II antigens on nonhematopoietic tumor cells
EA199900902A1 (ru) Моноклональное антитело, распознающее в злокачественных опухолях олигосахарид n-гликолилированная галактоза-глюкоза сиаловая кислота, и композиция, которая его содержит
Fuks et al. Local control is associated with decreased distant failure in early stage carcinoma of the prostate
US20200230265A1 (en) Anti-cd33 antibody-guided imaging and treatment of acute myeloid leukemia
Lahorte et al. Radiolabeling, biodistribution, and dosimetry of 123I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo
Russell et al. Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer

Legal Events

Date Code Title Description
FG Grant, registration